It has also been shown to have beneficial effects in obesity-related hyperinsulinemia and in improving energy homeostasis.14 It has been shown that serum adropin levels decrease in many diseases such as coronary atherosclerosis, hypertension, diabetic nephropathy, and polycystic ovary disease.15,16 Clinical studies have confirmed that serum adropin levels are negatively correlated with the risk factors of metabolic diseases. Here, ENHO is linked to obesity disorder.